REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled Trial

First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.

Gatlik Ewa, Mehes Beata, Voltz Emilie, Sommer Ulrike, Tritto Elaine, Lestini Giulia, Liu Xiaoxi, Pal Parasar, Velinova Maria, Denney Wiliam S
Clinical and translational science2024DOI: 10.1111/cts.13789

Citations

0

Subjects

Non-Human

Study Context

Randomized controlled trials are the gold standard for evaluating treatment efficacy. The randomized design minimizes bias, making findings more reliable for clinical decision-making.

Citation

Gatlik Ewa, Mehes Beata, Voltz Emilie et al.. (2024). First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.. Clinical and translational science. https://doi.org/10.1111/cts.13789

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.